| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/14651858.CD011893 |
| P2093 | author name string | Siree Kaempfen | |
| Sven M Schulzke | |||
| Kerstin Jost | |||
| Roland P Neumann | |||
| P2860 | cites work | Cochrane Database of Systematic Reviews | Q15750361 |
| Bronchopulmonary dysplasia | Q28201380 | ||
| GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables | Q29547885 | ||
| The biology of vascular endothelial growth factor | Q29615946 | ||
| GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias) | Q29619791 | ||
| Mid- and long-term outcome of extremely low birth weight (ELBW) infants: an analysis of prognostic factors | Q33292987 | ||
| Peripheral retinal ablation for threshold retinopathy of prematurity in preterm infants | Q33908324 | ||
| Neurodevelopmental outcome of extremely low birth weight infants from the Vermont Oxford network: 1998-2003 | Q33928084 | ||
| Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. | Q34034894 | ||
| Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging | Q34051652 | ||
| Pathogenesis of retinopathy of prematurity | Q34546104 | ||
| A randomized, controlled trial of oral propranolol in infantile hemangioma. | Q34668015 | ||
| Oral Propranolol: A New Treatment for Infants with Retinopathy of Prematurity? | Q35629247 | ||
| Are 1-2 tablets dangerous? Beta-blocker exposure in toddlers | Q35694668 | ||
| Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy | Q36035023 | ||
| Retinal and choroidal microangiopathies: therapeutic opportunities. | Q36856719 | ||
| Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control | Q37072107 | ||
| Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. | Q37416041 | ||
| Effects of beta-blockers on glucose and lipid metabolism | Q37672633 | ||
| GRADE guidelines: 8. Rating the quality of evidence--indirectness | Q37908616 | ||
| GRADE guidelines: 7. Rating the quality of evidence--inconsistency | Q37908778 | ||
| The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge | Q38101684 | ||
| The β-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases | Q38220562 | ||
| Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the β-adrenergic system. | Q38293740 | ||
| On the use of antiangiogenetic medications for retinopathy of prematurity | Q38906895 | ||
| Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia | Q40561597 | ||
| Incidence and evolution of subependymal and intraventricular hemorrhage: A study of infants with birth weights less than 1,500 gm | Q40671726 | ||
| Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia | Q40935597 | ||
| Hyperkalemia complicating propranolol treatment of an infantile hemangioma | Q42790586 | ||
| Severe hypoglycemia during successful treatment of diffuse hemangiomatosis with propranolol. | Q43034223 | ||
| Propranolol for complicated infantile haemangiomas: a case series of 30 infants | Q43200345 | ||
| Propranolol for severe infantile hemangiomas: follow-up report | Q43286268 | ||
| Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study | Q44983135 | ||
| Propranolol for severe hemangiomas of infancy. | Q46542573 | ||
| Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity | Q47310528 | ||
| Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants | Q48301793 | ||
| Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. | Q50442563 | ||
| Infantile hemangiomas and retinopathy of prematurity: possible association. | Q51818134 | ||
| Antiangiogenic effects of β2 -adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. | Q51851194 | ||
| GRADE guidelines 6. Rating the quality of evidence—imprecision | Q57269328 | ||
| Retinopathy of prematurity | Q60439193 | ||
| Pharmacokinetics and local safety profile of propranolol eye drops in rabbits | Q61700384 | ||
| Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor | Q73226153 | ||
| Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice | Q86489017 | ||
| Dangers of propranolol in preterm infants | Q87179700 | ||
| Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study | Q87493038 | ||
| P921 | main subject | retinopathy of prematurity | Q1423087 |
| preterm infant | Q45051448 | ||
| P577 | publication date | 2015-09-28 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants |
Search more.